Invenomic Capital Management

Ali Motamed, founder and portfolio manager, maintains centralized decision authority over all positions. He is supported by a research team but operates without a traditional investment committee — a single-accountability structure that allows rapid portfolio adjustments. Before founding Invenomic, Motamed managed a long/short financials book at Balyasny Asset Management and previously worked at Citadel and McKinsey & Company.

The firm relies on deep fundamental research and proprietary forensic accounting analysis rather than sell-side networks or quantitative screens. Motamed's team focuses on misunderstood, underfollowed, or structurally complex companies where consensus pricing breaks down. The approach emphasizes catalyst identification — specific events or disclosures that will force market repricing — rather than passive value exposure.

No. Invenomic is structured as a unified single-manager fund where Motamed controls all investment decisions, unlike the pod-shop model employed by his former firms. There are no independent risk-taking portfolio managers, and the firm has not expanded through external team acquisitions. This structure produces a concentrated, high-conviction book rather than hundreds of loosely correlated positions.

The firm typically maintains 15-25 long positions with a smaller, actively managed short sleeve. Sector exposures cluster in real estate investment trusts, healthcare services, financials, and consumer cyclicals — areas where Motamed has deep analytical history. Position sizing reflects conviction rather than benchmark weights, resulting in meaningful tracking error against broad equity indices.

The firm closed its flagship fund to new investors in 2021, signaling capacity discipline. While occasional capacity may open for existing relationships, the general posture is capacity-constrained — consistent with Motamed's stated preference for managing a concentrated book rather than scaling assets at the expense of strategy integrity (per SEC filings and public record).

The firm generated significant positive returns during both stress periods — a track record that distinguishes it from long/short peers who struggled in those environments. Motamed's catalyst-driven approach and willingness to maintain elevated short exposure during overvalued markets contributed to the asymmetrical payoff profile. Detailed performance figures are not publicly disclosed given the firm's private partnership structure.

The firm's limited partner base includes endowments, foundations, and public pension funds — institutions that typically require multi-year track records, operational due diligence, and transparency. This institutional composition reflects the firm's rapid post-launch credibility in the Boston allocator community. Invenomic does not actively market to high-net-worth individuals or retail platforms.